A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway

Molecular Cancer Therapeutics

Volumn 3, Issue 7, 2004, Pages 885-893

  Zhang, Yuesheng ^a   Gordon, Gary B ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DITHIOLE 3 THIONE DERIVATIVE; 3H 1,2 DITHIOLE 3 THIONE DERIVATIVE; 4' BROMOFLAVONE; 6 METHYLSULFINYLHEXYL ISOTHIOCYANATE; ALPHA TOCOPHEROL DERIVATIVE; ALPHA TOCOPHERYLQUINOL; ANETHOLE TRITHIONE; ANTINEOPLASTIC AGENT; BUTYLATED HYDROXYANISOLE; CARCINOGEN; ETHOXYQUIN; FLAVONE DERIVATIVE; GLUTATHIONE TRANSFERASE; ISOTHIOCYANIC ACID DERIVATIVE; OLTIPRAZ; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SULFORAPHANE; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DNA ADDUCT; DNA BINDING; DNA RESPONSIVE ELEMENT; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME DEFICIENCY; GASTROINTESTINAL SYMPTOM; GENE CONTROL; GENE DISRUPTION; GENE EXPRESSION; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PAIN; PARESTHESIA; PRIORITY JOURNAL; REGULATOR GENE; SHORT SURVEY; SIGNAL TRANSDUCTION; SKIN TINGLING; UPREGULATION;

ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; NF-E2-RELATED FACTOR 2; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS;

EID: 4444315787     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (129)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Talalay P. The war against cancer: new hope. Proc Am Philos Soc 1999;143:52-72.
3. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21:525-30.
4. Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 1999;59:4743-58.
5. Kelloff GJ, Sigman CC, Greenwald P. Cancer chemoprevention: progress and promise. Eur J Cancer 1999;35:2031-8.
6. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res 2002;62:5119-25.
7. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46.
8. Guengerich FP. Metabolism of chemical carcinogens. Carcinogenesis 2000;21:345-51.
9. Nebbia C. Biotransformation enzymes as determinants of xenobiotic toxicity in domestic animals. Vet J 2001;161:238-52.
10. Anzenbacher P, Anzenbacherovâa E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737-47.
11. Wilkinson JT, Clapper ML. Detoxication enzymes and chemoprevention. Proc Soc Exp Biol Med 1997;216:192-200.
12. Hinson JA, Forkert PG. Phase II enzymes and bioactivation. Can J Physiol Pharmacol 1995;73:1407-13.
13. Cantelli-Forti G, Hrelia P, Paolini M. The pitfall of detoxifying enzymes. Mutat Res 1998;402:179-83.
14. van Bladeren PJ. Glutathione conjugation as a bioactivation reaction. Chem Biol Interact 2000;129:61-76.
15. Buetler TM, Gallagher EP, Wang C, Stahl DL, Hayes JD, Eaton DL. Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz. Toxicol Appl Pharmacol 1995;135:45-57.
16. Prestera T, Zhang Y, Spencer SR, Wilczak CA, Talalay P. The electrophile counterattack response: protection against neoplasia and toxicity. Adv Enzyme Regul 1993;33:281-96.
17. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003;278:12029-38.
18. Chanas SA, Jiang Q, McMahon M, et al. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem J 2002;365 Pt 2:405-16.
19. Morimitsu Y, Nakagawa Y, Hayashi K, et al. A sulforaphane analogue that potently activates the Nrf2-dependent detoxification pathway. J Biol Chem 2002;277:3456-63.
20. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997;236: 313-22.
21. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002;62:5196-203.
22. Petri N, Tannergren C, Holst B, et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos 2003;31:805-13.
23. Ramos-Gomez M, Kwak M, Dolan PM, Itoh K, Yamamoto M, Talalay P. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 2001;98:3410-5.
24. Kim YC, Yamaguchi Y, Kondo N, Masutani H, Yodoi J. Thioredox-independent redox regulation of the antioxidant responsive element (ARE) in electrophile response. Oncogene 2003;22:1860-5.
25. Pietsch EC, Chan JY, Torti FM, Torti SV. Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem 2003;278:2361-9.
26. Park EY, Rho HM. The transcriptional activation of the human copper/zinc superoxide dismutase gene by 2,3,7,8-tetrachlorodibenzo-p-dioxin through two different regulator sites, the antioxidant responsive element and xenobiotic responsive element. Mol Cell Biochem 2002; 24:47-55.
27. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 2003;278:8135-45.
28. Li J, Lee JM, Johnson JA. Microarray analysis reveals an antioxidant responsive element-driven gene set involved in conferring protection from an oxidative stress-induced apoptosis in IMR-32 cells. J Biol Chem 2002; 277:388-94.
29. Rushmore TH, King RG, Paulson KE, Pickett CB. Regulation of glutathione S-transferase Ya subunit gene expression: identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc Natl Acad Sci USA 1990;87:3826-30.
30. Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 1991; 266:11632-9.
31. Prestera T, Holtzclaw WD, Zhang Y, Talalay P. Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci USA 1993;90:2965-9.
32. Zhang Y, Gonzalez V, Xu MJ. Expression and regulation of glutathione S-transferase P1-1 in cultured human epidermal cells. J Dermatol Sci 2002;30:205-14.
33. Nioi P, McHahon M, Itoh K, Yamamoto M, Hayes JD. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem J 2003;374:337-48.
34. Li Y, Jaiswal AK. Regulation of human NAD(P)H:quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element. J Biol Chem 1992;267:15097-104.
35. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 1996;93:14960-5.
36. Wilkinson J, Radjendirane V, Pfeiffer GR, Jaiswal AK, Clapper ML. Disruption of c-Fos leads to increased expression of NAD(P)H:quinone oxidoreductase1 and glutathione S-transferase. Biochem Biophys Res Commun 1998;253:855-8.
37. Nguyen T, Rushmore TH, Pickett CB. Transcriptional regulation of a rat liver glutathione S-transferase Ya subunit gene. Analysis of the antioxidant response element and its activation by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem 1994;269:13656-62.
38. Talalay P, De Long MJ, Prochaska HJ. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc Natl Aced Sci USA 1988;85:8261-5.
39. Prochaska HJ, De Long MJ, Talalay P. On the mechanisms of induction of cancer-protective enzymes: a unifying proposal. Proc Natl Acad Sci USA 1985;82:8232-6.
40. Spencer SR, Xue L, Klenz EM, Talalay P. The potency of inducers of NAD(P)H:(quinone-acceptor) oxidoreductase parallels their efficiency as substrates for glutathione transferases. Biochem J 1991;273:711-7.
41. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999;13:76-86.
42. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the β-globin locus control region. Proc Natl Acad Sci USA 1994;91:9926-30.
43. Chan K, Lu R, Chang JC, Kan YW. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci USA 1996;93:13943-8.
44. Chan K, Kan YW. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci USA 1999;96:12731-6.
45. Kwak MK, Itoh K, Yamamoto M, Kensler TW. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol 2002;22:2883-92.
46. McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 2003;278:21592-600.
47. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 2002;99:11908-13.
48. Zipper LM, Mulcahy RT, The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem 2002;277: 36544-52.
49. Dhakshinamoorthy S, Jaiswal AK. Small maf (MafG and MafK) proteins negatively regulate antioxidant response element-mediated expression and antioxidant induction of the NAD(P)H:quinone oxidoreductase1 gene. J Biol Chem 2000;275:40134-41.
50. Dhakshinamoorthy S, Jaiswal AK. c-Maf negatively regulates ARE-mediated detoxifying enzyme genes expression and anti-oxidant induction. Oncogene 2002;21:5301-12.
51. Venugopal R, Jaiswal AK. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 1998;17:3145-56.
52. Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 1996;93:14960-5.
53. Kobayashi A, Ito E, Toki T, et al. Molecular cloning and functional characterization of a new cap 'n' collar family transcription factor Nrf3. J Biol Chem 1999;274:6443-52.
54. Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 2002;277:42769-74.
55. Zhu M, Fahl WE. Functional characterization of transcription regulators that interact with the electrophile response element. Biochem Biophys Res Commun 2001;289:212-9.
56. Yu R, Chen C, Mo YY, et al. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J Biol Chem 2000;275: 39907-13.
57. Yu R, Mandlekar S, Lei W, Fahl WE, Tan TH, Kong AT. p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J Biol Chem 2000; 275:2322-7.
58. Kang KW, Lee SJ, Park JW, Kim SG. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-regulated factor 2 through actin rearrangement in response to oxidative stress. Mol Pharmacol 2002;62: 1001-10.
59. Lee J-M, Hanson JM, Chu WA, Johnson JA. Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J Biol Chem 2001;276:20011-6.
60. Kang KW, Ryu JH, Kim SG. The essential role of phosphatidylinositol 3-kinase and of p38 mitogen-activated protein kinase activation in the antioxidant response element-mediated rGSTA2 induction by decreased glutathione in H4IIE hepatoma cells. Mol Pharmacol 2000;58:1017-25.
61. Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 2003;43:233-60.
62. Fahey JW, Haristoy X, Dolan PM, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci USA 2002;99:7610-5.
63. Ramos-Gomez M, Dolan PM, Itoh K, Yamamoto M, Kensler TW. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 2003;24:461-7.
64. Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, Yamamoto M. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol Appl Pharmacol 2001;173:154-60.
65. Enomoto A, Itoh K, Nagayoshi E, et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001;59:169-77.
66. Favreau LV, Pickett CE. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Identification of regulatory elements controlling basal level expression and inducible expression by planar aromatic compounds and phenolic antioxidants. J Biol Chem 1991;266: 4556-61.
67. Dinkova-Kostova AT, Talalay P. Persuasive evidence that quinone reductase type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen. Free Radic Biol Med 2000; 29:231-40.
68. Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA 2002;99: 3099-104.
69. Joseph P, Long DJ II, Klein-Szanto AJ, Jaiswal AK. Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. Biochem Pharmacol 2000;60:207-14.
70. Joseph P, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci USA 1994;91:8413-7.
71. Long DJ II, Waikel RL, Wang XJ, Perlaky L, Roop DR, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res 2000; 60:5913-5.
72. Long DJ II, Waikel RL, Wang XJ, Roop DR, Jaiswal AK. NAD(P)H:-quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. J Natl Cancer Inst 2001;93:1166-70.
73. Begleiter A, Sivananthan K, Curphey TJ, Bird RP. Induction of NAD(P)H quinone:oxidoreductase1 inhibits carcinogen-induced aberrant crypt foci in colons of Sprague-Dawley rats. Cancer Epidemiol Biomarkers & Prev 2003;12:566-72.
74. Rothman N, Smith MT, Hayes RB, et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609CT mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 1997;57:2839-42.
75. Schulz WA, Krummeck A, Rèosinger I, et al. Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 1997;7:235-9.
76. Clairmont A, Sies H, Ramachandran S, et al. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci. Carcinogenesis 1999; 20:1235-40.
77. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers & Prev 1997;6:87-92.
78. Xu LL, Wain JC, Miller DP, et al. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers & Prev 2001; 10:303-9.
79. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30: 445-600.
80. Whitbread AK, Tetlow N, Eyre HJ, Sutherland GR, Board PG. Characterization of the human ω class glutathione transferase genes and associated polymorphisms. Pharmacogenetics 2003;13:131-44.
81. Whalen R, Boyer TD. Human glutathione S-transferases. Semin Liver Dis 1998;18:345-58.
82. Ikeda H, Serria MS, Kakizaki I, et al. Activation of mouse π-class glutathione S-transferase gene by Nrf2(NF-E2-related factor 2) and androgen. Biochem J 2002;364 Pt 2:563-70.
83. Brooks JD, Paton VG, Vidanes G. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers & Prev 2001;10:949-54.
84. Jiang ZQ, Chen C, Yang B, Hebbar V, Kong AN. Differential responses from seven mammalian cell lines to the treatments of detoxifying enzyme inducers. Life Sci 2003;72:2243-53.
85. Ketterer B, Meyer DJ, Coles B, Taylor JB, Pemble S. Glutathione transferases and carcinogenesis. Basic Life Sci 1986;39:103-26.
86. Mannervik B, Danielson UH. Glutathione transferases - structure and catalytic activity. CRC Crit Rev Biochem 1988;23:283-337.
87. Henderson CJ, Smith AG, Ure J, Brown K, Bacon EJ, Wolf CR. Increased skin tumorigenesis in mice lacking π class glutathione S-transferases. Proc Natl Acad Sci USA 1998;95:5275-80.
88. Mannervik B. Novel polymorphisms in the glutathione transferase superfamily. Pharmacogenetics 2003;13:127-8.
89. Zheng T, Holford TR, Zahm SH, et al. Glutathione S-transferase M1 and T1 genetic polymorphisms, alcohol consumption and breast cancer risk. Br J Cancer 2003;88:58-62.
90. Laso N, Lafuente MJ, Mas S, et al. Glutathione S-transferase (GSTM1 and GSTT1)-dependent-risk for colorectal cancer. Anticancer Res 2002;22:3399-403.
91. Morari EC, Leite JL, Granja F, da Assumpcäo LV, Ward LS. The null genotype of glutathione S-transferase M1 and T1 locus increases the risk for thyroid cancer. Cancer Epidemiol Biomarkers & Prev 2002; 11:1485-8.
92. Perera FP, Mooney LA, Stampfer M, et al. Associations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians' Health Cohort Study. Carcinogenesis 2002;23:1641-6.
93. Cai L, Yu SZ, Zhang ZF. Glutathione S-transferases M1, T1 genotypes and the risk of gastric cancer: a case-control study. World J Gastroenterol 2001;7:506-9.
94. Kote-Jarai Z, Easton D, Edwards SM, et al. Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics 2001;11:325-30.
95. Anwar WA, Abdel-Rahman SZ, El-Zein RA, Mostafa HM, Au WW. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 1996;17:1923-9.
96. Aktas D, Ozen H, Atsu N, Tekin A, Sozen S, Tuncbilek E. Glutathione S-transferase M1 gene polymorphism in bladder cancer patients. A marker for invasive bladder cancer? Cancer Genet Cytogenet 2001;125:1-4.
97. Georgiou I, Filiadis IF, Alamanos Y, Bouba I, Giannakopoulos X, Lolis D. Glutathione S-transferase null genotypes in transitional cell bladder cancer: a case-control study. Eur Urol 2000;37:660-4.
98. Toruner CA, Akyerli C, Ucar A, et al. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Arch Toxicol 2001;75:459-64.
99. Johns LE, Houlston RS. Glutathione S-transferase μl (GSTM1) status and bladder cancer risk: a meta-analysis. Mutagenesis 2000;15: 399-404.
100. Salagovic J, Kalina I, Habalova V, Hrivnak M, Valansky L, Biros E. The role of human glutathione S-transferases M1 and T1 in individual susceptibility to bladder cancer. Physiol Res 1999;48:465-71.
101. De Long MJ, Prochaska HJ, Talalay P. Induction of NAD(P)H:quinone reductase in murine hepatoma cells by phenolic antioxidants, azo dyes, and other chemoprotectors: a model system for the study of anticarcinogens. Proc Natl Acad Sci USA 1986;83:787-91.
102. Prochaska HJ, Santamaria AB. Direct measurement of NAD(P)H: quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 1988;169:328-36.
103. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 1992;89:2399-403.
104. Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 1994;91:3147-50.
105. Zhu M, Fahl WE. Development of a green fluorescent protein microplate assay for the screening of chemopreventive agents. Anal Biochem 2000;287:210-7.
106. Brooks JD, Goldberg MF, Nelson LA, Wu D, Nelson WG. Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro. Cancer Epidemiol Biomarkers & Prev 2002;11:868-75.
107. Primiano T, Sutter TR, Kensler TW. Antioxidant-inducible genes. Adv Pharmacol 1997;38:293-328.
108. Kensler TW, Groopman JD, Sutter TR, Curphey TJ, Roebuck ED. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem Res Toxicol 1999;12:113-26.
109. Kensler TW, Helzlsouer KJ. Oltipraz: clinical opportunities for cancer chemoprevention. J Cell Biochem 1995;22 Suppl:101-7.
110. Kensler TW, Davidson NE, Egner PA, et al. Mechanisms of chemoprotection against aflatoxin-induced hepatocarcinogenesis by oltipraz. In: Nygaard OF, Upton AC. editors. Anticarcinogenesis and radiation protection 2. New York: Plenum Press; 1991.
111. Kensler TW. Chemoprevention by inducers of carcinogen detoxication enzymes. Environ Health Perspect 1997;105 Suppl 4:965-70.
112. Jacobson LP, Zhang BC, Zhu YR, et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers & Prev 1997; 6:257-65.
113. Wang JS, Shen X, He X, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999;91:347-54.
114. Kensler TW, He X, Otieno M, et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol Biomarkers & Prev 1998;7:127-34.
115. Camoirano A, Bagnasco M, Bennicelli C, et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: results of urine genotoxicity assays as related to smoking habits. Cancer Epidemiol Biomarkers & Prev 2001;10:775-83.
116. Kensler TW, Groopman JD, Roebuck BD. Chemoprotection by oltipraz and other dithiolethiones. In: Wattenberg L, Lipkin M, Boone C, Kelloff G, editors. Cancer chemoprevention. Boca Raton: CRC Press; 1992. p. 205-25.
117. Reddy BS, Rao CV, Rivenson A, Kelloff G. Chemoprevention of colon carcinogenesis by organosulfur compounds. Cancer Res 1993;53: 3493-8.
118. Kensler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res 1987;47:4271-7.
119. Warnet JM, Christen MO, Thevenin M, Biard D, Jacqueson A, Claude JR. Protective effects of anethole dithiolethione against acetaminophen hepatotoxicity in mice. Pharmacol Toxicol 1989;65:63-4.
120. Remick RA, Blasberg B, Patterson BD, Carmichael RP, Miles JE. Clinical aspects of xerostomia. J Clin Psychiatry 1983;44:63-5.
121. Epstein JB, Decoteau WE, Wilkinson A. Effect of Sialor in treatment of xerostomia in Sjèogren's syndrome. Oral Surg Oral Mad Oral Pathol 1983;56:495-9.
122. Lam S, MacAulay C, Le Riche JC, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002;94:1001-9.
123. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 1997;94:10367-72.
124. Zhang Y. Cancer chemoprevention with sulforaphane, a dietary isothiocyanate. In: Bao Y, Fenwick R, editors. Phytochemicals in health and disease. New York: Marcel Dekker; in press.
125. Gills JJ, Jeffery EH, Moon RC, Lantvit DD, Pezzuto JM. Effects of sulforaphane on UVB-induced skin carcinogenesis. Proc Am Assoc Cancer Res 2003;44:223.
126. Chung FL, Conaway CC, Rao CV, Reddy BS. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 2000;21:2287-91.
127. Ye L, Dinkova-Kostova AT, Wade KL, Zhang Y, Shapiro TA, Talalay P. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta 2002;316:43-53.
128. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. Cancer Epidemiol Biomarkers & Prev 2001;10:501-8.
129. Song LL, Kosmeder JW II, Lee SK, et al. Cancer chemopreventive activity mediated by 4′-bromoflavone, a potent inducer of phase II detoxification enzymes. Cancer Res 1999;59:578-85.